Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 2, 2011, Pages 151-161

  Mars, Lennart T ^a,b   Saikali, Philippe ^c,d   Liblau, Roland S ^a,b   Arbour, Nathalie ^a  

^a CHU PURPAN   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Autoimmunity; Central nervous system; Cytotoxic T cell; Demyelination; Suppressor cell; T lymphocyte

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN ANTIBODY REACTION; ANTIGEN PRESENTATION; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL SPECIFICITY; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM INFECTION; DEMYELINATION; DISEASE ASSOCIATION; EFFECTOR CELL; EPSTEIN BARR VIRUS; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PATHOGENICITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; VIRUS INFECTION;

ANIMALIA;

EID: 78650175567     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.07.006     Document Type: Review

References (164)

1. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
2. McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007, 8:913-919.
3. Kabat E.A., Wolf A., Bezer A.E., Murray J.P. Studies on acute disseminated encephalomyelitis produced experimentally in rhesus monkeys. J. Exp. Med. 1951, 93:615-633.
4. Baxter A.G. The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 2007, 7:904-912.
5. Llewellyn-Smith N., Lai M., Miller D.H., Rudge P., Thompson A.J., Cuzner M.L. Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412. Neurology 1997, 48:810-816.
6. Rep M.H., van Oosten B.W., Roos M.T., Ader H.J., Polman C.H., van Lier R.A. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. J. Clin. Invest. 1997, 99:2225-2231.
7. van Oosten B.W., Lai M., Hodgkinson S., Barkhof F., Miller D.H., Moseley I.F., Thompson A.J., Rudge P., McDougall A., McLeod J.G., Ader H.J., Polman C.H. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997, 49:351-357.
8. Lindsey J.W., Hodgkinson S., Mehta R., Mitchell D., Enzmann D., Steinman L. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann. Neurol. 1994, 36:183-189.
9. Friese M.A., Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?. Brain 2005, 128:1747-1763.
10. Zozulya A.L., Wiendl H. The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation. Hum. Immunol. 2008, 69:797-804.
11. Townsend A.R., Rothbard J., Gotch F.M., Bahadur G., Wraith D., McMichael A.J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986, 44:959-968.
12. Davis M.M., Boniface J.J., Reich Z., Lyons D., Hampl J., Arden B., Chien Y. Ligand recognition by alpha beta T cell receptors. Annu. Rev. Immunol. 1998, 16:523-544.
13. Williams M.A., Bevan M.J. Effector and memory CTL differentiation. Annu. Rev. Immunol. 2007, 25:171-192.
14. Harty J.T., Tvinnereim A.R., White D.W. CD8+ T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 2000, 18:275-308.
15. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
16. Harty J.T., Badovinac V.P. Shaping and reshaping CD8+ T-cell memory. Nat. Rev. Immunol. 2008, 8:107-119.
17. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 2004, 22:745-763.
18. Oldstone M.B., Blount P., Southern P.J., Lampert P.W. Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature 1986, 321:239-243.
19. Melzer N., Meuth S.G., Wiendl H. CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB J. 2009, 23:3659-3673.
20. Medana I.M., Gallimore A., Oxenius A., Martinic M.M., Wekerle H., Neumann H. MHC class I-restricted killing of neurons by virus-specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway. Eur. J. Immunol. 2000, 30:3623-3633.
21. Medana I., Li Z., Flugel A., Tschopp J., Wekerle H., Neumann H. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity. J. Immunol. 2001, 167:674-681.
22. Wang T., Allie R., Conant K., Haughey N., Turchan-Chelowo J., Hahn K., Rosen A., Steiner J., Keswani S., Jones M., Calabresi P.A., Nath A. Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J. 2006, 20:1209-1211.
23. Medana I., Martinic M.A., Wekerle H., Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 2001, 159:809-815.
24. Saikali P., Antel J.P., Newcombe J., Chen Z., Freedman M., Blain M., Cayrol R., Prat A., Hall J.A., Arbour N. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J. Neurosci. 2007, 27:1220-1228.
25. Khoury S.J., Guttmann C.R., Orav E.J., Kikinis R., Jolesz F.A., Weiner H.L. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch. Neurol. 2000, 57:1183-1189.
26. Laplaud D.A., Berthelot L., Miqueu P., Bourcier K., Moynard J., Oudinet Y., Guillet M., Ruiz C., Oden N., Brouard S., Guttmann C.R., Weiner H.L., Khoury S.J., Soulillou J.P. Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters. J. Neuroimmunol. 2006, 177:151-160.
27. Rinaldi L., Gallo P., Calabrese M., Ranzato F., Luise D., Colavito D., Motta M., Guglielmo A., Del Giudice E., Romualdi C., Ragazzi E., D'Arrigo A., Dalle Carbonare M., Leontino B., Leon A. Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. Brain 2006, 129:1993-2007.
28. Laplaud D.A., Ruiz C., Wiertlewski S., Brouard S., Berthelot L., Guillet M., Melchior B., Degauque N., Edan G., Brachet P., Damier P., Soulillou J.P. Blood T-cell receptor beta chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution. Brain 2004, 127:981-995.
29. Liu G.Z., Fang L.B., Hjelmstrom P., Gao X.G. Increased CD8+ central memory T cells in patients with multiple sclerosis. Mult. Scler. 2007, 13:149-155.
30. Killestein J., Eikelenboom M.J., Izeboud T., Kalkers N.F., Ader H.J., Barkhof F., Van Lier R.A., Uitdehaag B.M., Polman C.H. Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS. J. Neuroimmunol. 2003, 142:141-148.
31. Eikelenboom M.J., Killestein J., Izeboud T., Kalkers N.F., van Lier R.A., Barkhof F., Uitdehaag B.M., Polman C.H. Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis. J. Neuroimmunol. 2002, 133:225-232.
32. Battistini L., Piccio L., Rossi B., Bach S., Galgani S., Gasperini C., Ottoboni L., Ciabini D., Caramia M.D., Bernardi G., Laudanna C., Scarpini E., McEver R.P., Butcher E.C., Borsellino G., Constantin G. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 2003, 101:4775-4782.
33. Bertrams H.J., Kuwert E.K. Association of histocompatibility haplotype HLA-A3-B7 with multiple sclerosis. J. Immunol. 1976, 117:1906-1912.
34. Harbo H.F., Lie B.A., Sawcer S., Celius E.G., Dai K.Z., Oturai A., Hillert J., Lorentzen A.R., Laaksonen M., Myhr K.M., Ryder L.P., Fredrikson S., Nyland H., Sørensen P.S., Sandberg-Wollheim M., Andersen O., Svejgaard A., Edland A., Mellgren S.I., Compston A., Vartdal F., Spurkland A. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens 2004, 63:237-247.
35. Fogdell-Hahn A., Ligers A., Gronning M., Hillert J., Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000, 55:140-148.
36. Rubio J.P., Bahlo M., Stankovich J., Burfoot R.K., Johnson L.J., Huxtable S., Butzkueven H., Lin L., Taylor B.V., Speed T.P., Kilpatrick T.J., Mignot E., Foote S.J. Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients. Immunogenetics 2007, 59:177-186.
37. Brynedal B., Duvefelt K., Jonasdottir G., Roos I.M., Akesson E., Palmgren J., Hillert J. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One 2007, 2:e664.
38. Bevan M. Cross-priming. Nat. Immunol. 2006, 7:363-365.
39. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 1994, 152:163-175.
40. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
41. Tsuchida T., Parker K.C., Turner R.V., McFarland H.F., Coligan J.E., Biddison W.E. Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:10859-10863.
42. Dressel A., Chin J.L., Sette A., Gausling R., Hollsberg P., Hafler D.A. Autoantigen recognition by human CD8 T cell clones: enhanced agonist response induced by altered peptide ligands. J. Immunol. 1997, 159:4943-4951.
43. Zang Y.C., Li S., Rivera V.M., Hong J., Robinson R.R., Breitbach W.T., Killian J., Zhang J.Z. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J. Immunol. 2004, 172:5120-5127.
44. Banki K., Colombo E., Sia F., Halladay D., Mattson D.H., Tatum A.H., Massa P.T., Phillips P.E., Perl A. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J. Exp. Med. 1994, 180:1649-1663.
45. Crawford M.P., Yan S.X., Ortega S.B., Mehta R.S., Hewitt R.E., Price D.A., Stastny P., Douek D.C., Koup R.A., Racke M.K., Karandikar N.J. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004, 103:4222-4231.
46. Niland B., Banki K., Biddison W.E., Perl A. CD8+ T cell-mediated HLA-A*0201-restricted cytotoxicity to transaldolase peptide 168-176 in patients with multiple sclerosis. J. Immunol. 2005, 175:8365-8378.
47. Jurewicz A., Biddison W.E., Antel J.P. MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J. Immunol. 1998, 160:3056-3059.
48. Rus H., Pardo C.A., Hu L., Darrah E., Cudrici C., Niculescu T., Niculescu F., Mullen K.M., Allie R., Guo L., Wulff H., Beeton C., Judge S.I., Kerr D.A., Knaus H.G., Chandy K.G., Calabresi P.A. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11094-11099.
49. Berthelot L., Laplaud D.A., Pettre S., Ballet C., Michel L., Hillion S., Braudeau C., Connan F., Lefrere F., Wiertlewski S., Guillet J.G., Brouard S., Choppin J., Soulillou J.P. Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals. Eur. J. Immunol. 2008, 38:1889-1899.
50. Huizinga R., Hintzen R.Q., Assink K., van Meurs M., Amor S. T-cell responses to neurofilament light protein are part of the normal immune repertoire. Int. Immunol. 2009, 21:433-441.
51. Russell J.H., Ley T. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 2002, 20:323-370.
52. de Vos A.F., van Meurs M., Brok H.P., Boven L.A., Hintzen R.Q., van der Valk P., Ravid R., Rensing S., Boon L., 't Hart B.A., Laman J.D. Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J. Immunol. 2002, 169:5415-5423.
53. van Zwam M., Huizinga R., Melief M.J., Wierenga-Wolf A.F., van Meurs M., Voerman J.S., Biber K.P., Boddeke H.W., Höpken U.E., Meisel C., Meisel A., Bechmann I., Hintzen R.Q., 't Hart B.A., Amor S., Laman J.D., Boven L.A. Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J. Mol. Med. 2009, 87:273-286.
54. Calzascia T., Masson F., Di Berardino-Besson W., Contassot E., Wilmotte R., Aurrand-Lions M., Rüegg C., Dietrich P.Y., Walker P.R. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 2005, 22:175-184.
55. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N Engl J. Med. 2006, 354:942-955.
56. Calzascia T., Di Berardino-Besson W., Wilmotte R., Masson F., de Tribolet N., Dietrich P.Y., Walker P.R. Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J. Immunol. 2003, 171:2187-2191.
57. Höftberger R., Aboul-Enein F., Brueck W., Lucchinetti C., Rodriguez M., Schmidbauer M., Jellinger K., Lassmann H. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 2004, 14:43-50.
58. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., Friese M., Schroder R., Deckert M., Schmidt S., Ravid R., Rajewsky K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 2000, 192:393-404.
59. Jacobsen M., Cepok S., Quak E., Happel M., Gaber R., Ziegler A., Schock S., Oertel W.H., Sommer N., Hemmer B. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002, 125:538-550.
60. Skulina C., Schmidt S., Dornmair K., Babbe H., Roers A., Rajewsky K., Wekerle H., Hohlfeld R., Goebels N. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2428-2433.
61. Schwab N., Bien C.G., Waschbisch A., Becker A., Vince G.H., Dornmair K., Wiendl H. CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain 2009, 132:1236-1246.
62. Seitz S., Schneider C.K., Malotka J., Nong X., Engel A.G., Wekerle H., Hohlfeld R., Dornmair K. Reconstitution of paired T cell receptor alpha- and beta-chains from microdissected single cells of human inflammatory tissues. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12057-12062.
63. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
64. Hauser S.L., Bhan A.K., Gilles F., Kemp M., Kerr C., Weiner H.L. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann. Neurol. 1986, 19:578-587.
65. Neumann H., Medana I.M., Bauer J., Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 2002, 25:313-319.
66. Lassmann H. Recent neuropathological findings in MS-implications for diagnosis and therapy. J. Neurol. 2004, 251(Suppl 4):IV2-IV5.
67. Gay F.W., Drye T.J., Dick G.W., Esiri M.M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997, 120:1461-1483.
68. Junker A., Ivanidze J., Malotka J., Eiglmeier I., Lassmann H., Wekerle H., Meinl E., Hohlfeld R., Dornmair K. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 2007, 130:2789-2799.
69. Wulff H., Calabresi P.A., Allie R., Yun S., Pennington M., Beeton C., Chandy K.G. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J. Clin. Invest. 2003, 111:1703-1713.
70. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Capello E., Mancardi G.L., Aloisi F. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J. Neuropathol. Exp. Neurol. 2006, 65:124-141.
71. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172:146-155.
72. Jilek S., Schluep M., Rossetti A.O., Guignard L., Le Goff G., Pantaleo G., Du Pasquier R.A. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis. Clin. Immunol. 2007, 123:105-113.
73. Kivisäkk P., Mahad D.J., Callahan M.K., Sikora K., Trebst C., Tucky B., Wujek J., Ravid R., Staugaitis S.M., Lassmann H., Ransohoff R.M. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann. Neurol. 2004, 55:627-638.
74. Bromley S.K., Thomas S.Y., Luster A.D. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat. Immunol. 2005, 6:895-901.
75. Debes G.F., Arnold C.N., Young A.J., Krautwald S., Lipp M., Hay J.B., Butcher E.C. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat. Immunol. 2005, 6:889-894.
76. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000, 123(Pt 6):1174-1183.
77. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002, 125:2202-2212.
78. Mars L.T., Bauer J., Gross D.A., Bucciarelli F., Firat H., Hudrisier D., Lemonnier F., Kosmatopoulos K., Liblau R.S. CD8 T cell responses to myelin oligodendrocyte glycoprotein-derived peptides in humanized HLA-A*0201-transgenic mice. J. Immunol. 2007, 179:5090-5098.
79. Biddison W.E., Taub D.D., Cruikshank W.W., Center D.M., Connor E.W., Honma K. Chemokine and matrix metalloproteinase secretion by myelin proteolipid protein-specific CD8+ T cells: potential roles in inflammation. J. Immunol. 1997, 158:3046-3053.
80. Honma K., Parker K.C., Becker K.G., McFarland H.F., Coligan J.E., Biddison W.E. Identification of an epitope derived from human proteolipid protein that can induce autoreactive CD8+ cytotoxic T lymphocytes restricted by HLA-A3: evidence for cross-reactivity with an environmental microorganism. J. Neuroimmunol. 1997, 73:7-14.
81. Friese M.A., Jakobsen K.B., Friis L., Etzensperger R., Craner M.J., McMahon R.M., Jensen L.T., Huygelen V., Jones E.Y., Bell J.I., Fugger L. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat. Med. 2008, 14:1227-1235.
82. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 1995, 182:75-85.
83. Gregersen J.W., Kranc K.R., Ke X., Svendsen P., Madsen L.S., Thomsen A.R., Cardon L.R., Bell J.I., Fugger L. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 2006, 443:574-577.
84. Fugger L., Friese M.A., Bell J.I. From genes to function: the next challenge to understanding multiple sclerosis. Nat. Rev. Immunol. 2009, 9(6):408-417.
85. Huseby E.S., Liggitt D., Brabb T., Schnabel B., Ohlen C., Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J. Exp. Med. 2001, 194:669-676.
86. Panitch H.S., Hirsch R.L., Schindler J., Johnson K.P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987, 37:1097-1102.
87. Krakowski M., Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 1996, 26:1641-1646.
88. Ford M.L., Evavold B.D. Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2005, 35:76-85.
89. Sun D., Whitaker J.N., Huang Z., Liu D., Coleclough C., Wekerle H., Raine C.S. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 2001, 166:7579-7587.
90. Ben-Nun A., Kerlero de Rosbo N., Kaushansky N., Eisenstein M., Cohen L., Kaye J.F., Mendel I. Anatomy of T cell autoimmunity to myelin oligodendrocyte glycoprotein (MOG): prime role of MOG44F in selection and control of MOG-reactive T cells in H-2b mice. Eur. J. Immunol. 2006, 36:478-493.
91. Na S.Y., Cao Y., Toben C., Nitschke L., Stadelmann C., Gold R., Schimpl A., Hunig T. Naive CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain 2008, 131:2353-2365.
92. Saxena A., Bauer J., Scheikl T., Zappulla J., Audebert M., Desbois S., Waisman A., Lassmann H., Liblau R.S., Mars L.T. Cutting edge: multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes. J. Immunol. 2008, 181:1617-1621.
93. Cao Y., Toben C., Na S.Y., Stark K., Nitschke L., Peterson A., Gold R., Schimpl A., Hunig T. Induction of experimental autoimmune encephalomyelitis in transgenic mice expressing ovalbumin in oligodendrocytes. Eur. J. Immunol. 2006, 36:207-215.
94. Sobottka B., Harrer M.D., Ziegler U., Fischer K., Wiendl H., Hunig T., Becher B., Goebels N. Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. Am. J. Pathol. 2009, 175:1160-1166.
95. Bechmann I., Galea I., Perry V.H. What is the blood-brain barrier (not)?. Trends Immunol. 2007, 28:5-11.
96. Cabarrocas J., Bauer J., Piaggio E., Liblau R., Lassmann H. Effective and selective immune surveillance of the brain by MHC class I-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 2003, 33:1174-1182.
97. Readhead C., Schneider A., Griffiths I., Nave K.A. Premature arrest of myelin formation in transgenic mice with increased proteolipid protein gene dosage. Neuron 1994, 12:583-595.
98. Anderson T.J., Schneider A., Barrie J.A., Klugmann M., McCulloch M.C., Kirkham D., Kyriakides E., Nave K.A., Griffiths I.R. Late-onset neurodegeneration in mice with increased dosage of the proteolipid protein gene. J. Comp. Neurol. 1998, 394:506-519.
99. Ip C.W., Kroner A., Bendszus M., Leder C., Kobsar I., Fischer S., Wiendl H., Nave K.A., Martini R. Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. J. Neurosci. 2006, 26:8206-8216.
100. Kassmann C.M., Lappe-Siefke C., Baes M., Brugger B., Mildner A., Werner H.B., Natt O., Michaelis T., Prinz M., Frahm J., Nave K.A. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat. Genet. 2007, 39:969-976.
101. Fournier S., Rathmell J.C., Goodnow C.C., Allison J.P. T cell-mediated elimination of B7.2 transgenic B cells. Immunity 1997, 6:327-339.
102. Zehntner S.P., Brisebois M., Tran E., Owens T., Fournier S. Constitutive expression of a costimulatory ligand on antigen-presenting cells in the nervous system drives demyelinating disease. FASEB J. 2003, 17:1910-1912.
103. Brisebois M., Zehntner S.P., Estrada J., Owens T., Fournier S. A pathogenic role for CD8+ T cells in a spontaneous model of demyelinating disease. J. Immunol. 2006, 177:2403-2411.
104. Knickelbein J.E., Khanna K.M., Yee M.B., Baty C.J., Kinchington P.R., Hendricks R.L. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008, 322:268-271.
105. Brahic M., Bureau J.F., Michiels T. The genetics of the persistent infection and demyelinating disease caused by Theiler's virus. Annu. Rev. Microbiol. 2005, 59:279-298.
106. Miller S.D., Katz-Levy Y., Neville K.L., Vanderlugt C.L. Virus-induced autoimmunity: epitope spreading to myelin autoepitopes in Theiler's virus infection of the central nervous system. Adv. Virus Res. 2001, 56:199-217.
107. Vanderlugt C.L., Miller S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2002, 2:85-95.
108. Rivera-Quinones C., McGavern D., Schmelzer J.D., Hunter S.F., Low P.A., Rodriguez M. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat. Med. 1998, 4:187-193.
109. Murray P.D., Pavelko K.D., Leibowitz J., Lin X., Rodriguez M. CD4(+) and CD8(+) T cells make discrete contributions to demyelination and neurologic disease in a viral model of multiple sclerosis. J. Virol. 1998, 72:7320-7329.
110. Evans C.F., Horwitz M.S., Hobbs M.V., Oldstone M.B. Viral infection of transgenic mice expressing a viral protein in oligodendrocytes leads to chronic central nervous system autoimmune disease. J. Exp. Med. 1996, 184:2371-2384.
111. Matthews A.E., Weiss S.R., Paterson Y. Murine hepatitis virus-a model for virus-induced CNS demyelination. J. Neurovirol. 2002, 8:76-85.
112. Houtman J.J., Fleming J.O. Pathogenesis of mouse hepatitis virus-induced demyelination. J. Neurovirol. 1996, 2:361-376.
113. Wu G.F., Perlman S. Macrophage infiltration, but not apoptosis, is correlated with immune-mediated demyelination following murine infection with a neurotropic coronavirus. J. Virol. 1999, 73:8771-8780.
114. Wu G.F., Dandekar A.A., Pewe L., Perlman S. CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination. J. Immunol. 2000, 165:2278-2286.
115. Haring J.S., Pewe L.L., Perlman S. Bystander CD8 T cell-mediated demyelination after viral infection of the central nervous system. J. Immunol. 2002, 169:1550-1555.
116. Dandekar A.A., Anghelina D., Perlman S. Bystander CD8 T-cell-mediated demyelination is interferon-gamma-dependent in a coronavirus model of multiple sclerosis. Am. J. Pathol. 2004, 164:363-369.
117. Kim J.V., Kang S.S., Dustin M.L., McGavern D.B. Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis. Nature 2009, 457:191-195.
118. Ji Q., Perchellet A., Goverman J.M. Viral infection triggers central nervous system autoimmunity via activation of CD8(+) T cells expressing dual TCRs. Nat. Immunol. 2010, 11:628-634.
119. Prineas J.W. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979, 203:1123-1125.
120. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14:164-174.
121. Willis S.N., Stadelmann C., Rodig S.J., Caron T., Gattenloehner S., Mallozzi S.S., Roughan J.E., Almendinger S.E., Blewett M.M., Bruck W., Hafler D.A., O'Connor K.C. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009, 132:3318-3328.
122. Peferoen L.A., Lamers F., Lodder L.N., Gerritsen W.H., Huitinga I., Melief J., Giovannoni G., Meier U., Hintzen R.Q., Verjans G.M., van Nierop G.P., Vos W., Peferoen-Baert R.M., Middeldorp J.M., van der Valk P., Amor S. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 2010, 133:e137.
123. Hollsberg P., Hansen H.J., Haahr S. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin. Exp. Immunol. 2003, 132:137-143.
124. Pender M.P., Csurhes P.A., Lenarczyk A., Pfluger C.M., Burrows S.R. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2009, 80:498-505.
125. Jilek S., Schluep M., Meylan P., Vingerhoets F., Guignard L., Monney A., Kleeberg J., Le Goff G., Pantaleo G., Du Pasquier R.A. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008, 131:1712-1721.
126. Cepok S., Zhou D., Srivastava R., Nessler S., Stei S., Bussow K., Sommer N., Hemmer B. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest. 2005, 115:1352-1360.
127. Jiang H., Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J. Clin. Invest. 2004, 114:1198-1208.
128. Chess L., Jiang H. Resurrecting CD8+ suppressor T cells. Nat. Immunol. 2004, 5:469-471.
129. Antel J., Brown M., Nicholas M.K., Blain M., Noronha A., Reder A. Activated suppressor cell function in multiple sclerosis-clinical correlations. J. Neuroimmunol. 1988, 17:323-330.
130. Antel J.P., Bania M.B., Reder A., Cashman N. Activated suppressor cell dysfunction in progressive multiple sclerosis. J. Immunol. 1986, 137:137-141.
131. Chou Y.K., Henderikx P., Jones R.E., Kotzin B., Hashim G.A., Offner H., Vandenbark A.A. Human CD8+ T cell clone regulates autologous CD4+ myelin basic protein specific T cells. Autoimmunity 1992, 14:111-119.
132. Tennakoon D.K., Mehta R.S., Ortega S.B., Bhoj V., Racke M.K., Karandikar N.J. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J. Immunol. 2006, 176:7119-7129.
133. Biegler B.W., Yan S.X., Ortega S.B., Tennakoon D.K., Racke M.K., Karandikar N.J. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J. Neuroimmunol. 2006, 180:159-171.
134. Correale J., Villa A. Isolation and characterization of CD8+ regulatory T cells in multiple sclerosis. J. Neuroimmunol. 2008, 195:121-134.
135. Freedman M.S., Ruijs T.C., Blain M., Antel J.P. Phenotypic and functional characteristics of activated CD8+ cells: a CD11b-CD28- subset mediates noncytolytic functional suppression. Clin. Immunol. Immunopathol. 1991, 60:254-267.
136. Crucian B., Dunne P., Friedman H., Ragsdale R., Pross S., Widen R. Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin. Diagn. Lab. Immunol. 1995, 2:249-252.
137. Qin H., Vlad G., Cortesini R., Suciu-Foca N., Manavalan J.S. CD8+ suppressor and cytotoxic T cells recognize the same human leukocyte antigen-A2 restricted cytomegalovirus peptide. Hum. Immunol. 2008, 69:776-780.
138. Sze D.M., Giesajtis G., Brown R.D., Raitakari M., Gibson J., Ho J., Baxter A.G., Fazekas de St Groth B., Basten A., Joshua D.E. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood 2001, 98:2817-2827.
139. Correale J., Villa A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann. Neurol. 2010, 67:625-638.
140. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
141. Weiss H.A., Millward J.M., Owens T. CD8+ T cells in inflammatory demyelinating disease. J. Neuroimmunol. 2007, 191:79-85.
142. Jiang H., Zhang S.I., Pernis B. Role of CD8+ T cells in murine experimental allergic encephalomyelitis. Science 1992, 256:1213-1215.
143. Koh D.R., Fung-Leung W.P., Ho A., Gray D., Acha-Orbea H., Mak T.W. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science 1992, 256:1210-1213.
144. Linker R.A., Rott E., Hofstetter H.H., Hanke T., Toyka K.V., Gold R. EAE in beta-2 microglobulin-deficient mice: axonal damage is not dependent on MHC-I restricted immune responses. Neurobiol. Dis. 2005, 19:218-228.
145. Jiang H., Curran S., Ruiz-Vazquez E., Liang B., Winchester R., Chess L. Regulatory CD8+ T cells fine-tune the myelin basic protein-reactive T cell receptor V beta repertoire during experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8378-8383.
146. Jiang H., Braunstein N.S., Yu B., Winchester R., Chess L. CD8+ T cells control the TH phenotype of MBP-reactive CD4+ T cells in EAE mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6301-6306.
147. Jiang H., Ware R., Stall A., Flaherty L., Chess L., Pernis B. Murine CD8+ T cells that specifically delete autologous CD4+ T cells expressing V beta 8 TCR: a role of the Qa-1 molecule. Immunity 1995, 2:185-194.
148. Kumar V. Homeostatic control of immunity by TCR peptide-specific Tregs. J. Clin. Invest. 2004, 114:1222-1226.
149. Madakamutil L.T., Maricic I., Sercarz E., Kumar V. Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes. J. Immunol. 2003, 170:2985-2992.
150. Hu D., Ikizawa K., Lu L., Sanchirico M.E., Shinohara M.L., Cantor H. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat. Immunol. 2004, 5:516-523.
151. Lu L., Kim H.J., Werneck M.B., Cantor H. Regulation of CD8+ regulatory T cells: interruption of the NKG2A-Qa-1 interaction allows robust suppressive activity and resolution of autoimmune disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19420-19425.
152. Najafian N., Chitnis T., Salama A.D., Zhu B., Benou C., Yuan X., Clarkson M.R., Sayegh M.H., Khoury S.J. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J. Clin. Invest. 2003, 112:1037-1048.
153. Lee Y.H., Ishida Y., Rifa'i M., Shi Z., Isobe K., Suzuki H. Essential role of CD8+CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. J. Immunol. 2008, 180:825-832.
154. Stromnes I.M., Cerretti L.M., Liggitt D., Harris R.A., Goverman J.M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 2008, 14:337-342.
155. Galea I., Bernardes-Silva M., Forse P.A., van Rooijen N., Liblau R.S., Perry V.H. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J. Exp. Med. 2007, 204:2023-2030.
156. Hinrichs C.S., Kaiser A., Paulos C.M., Cassard L., Sanchez-Perez L., Heemskerk B., Wrzesinski C., Borman Z.A., Muranski P., Restifo N.P. Type 17 CD8+ T cells display enhanced anti-tumor immunity. Blood 2009, 114(3):596-599.
157. Ortega C., Fernandez A.S., Carrillo J.M., Romero P., Molina I.J., Moreno J.C., Santamaria M. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J. Leukoc. Biol. 2009, 86(2):435-443.
158. Roberts W.K., Deluca I.J., Thomas A., Fak J., Williams T., Buckley N., Dousmanis A.G., Posner J.B., Darnell R.B. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J. Clin. Invest. 2009, 119:2042-2051.
159. Vizler C., Bercovici N., Heurtier A., Pardigon N., Goude K., Bailly K., Combadiere C., Liblau R.S. Relative diabetogenic properties of islet-specific Tc1 and Tc2 cells in immunocompetent hosts. J. Immunol. 2000, 165:6314-6321.
160. Intlekofer A.M., Banerjee A., Takemoto N., Gordon S.M., Dejong C.S., Shin H., Hunter C.A., Wherry E.J., Lindsten T., Reiner S.L. Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 2008, 321:408-411.
161. Liblau R.S., Wong F.S., Mars L.T., Santamaria P. Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. Immunity 2002, 17:1-6.
162. Friese Manuel A., Fugger Lars Pathogenic CD8+ T cells in multiple sclerosis. Ann. Neurol. 2009, 9999. NA.
163. Coles A.J., Compston D.A., Selmaj K.W., Lake S.L., Moran S., Margolin D.H., Norris K., Tandon P.K. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis, N Engl. J. Med. 2008, 359:1786-1801.
164. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., Sandrock A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J. Med. 2006, 354:899-910.